12/16
08:01 am
kros
Rating for KROS
Medium
Report
Rating for KROS
12/16
08:01 am
kros
Rating for KROS
Medium
Report
Rating for KROS
12/16
07:05 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
Medium
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
12/16
07:05 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
Medium
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
12/16
05:17 am
kros
Rating for KROS
Medium
Report
Rating for KROS
12/16
05:17 am
kros
Rating for KROS
Medium
Report
Rating for KROS
12/15
07:14 pm
kros
Keros Therapeutics downgraded to Neutral from Buy at Guggenheim
Medium
Report
Keros Therapeutics downgraded to Neutral from Buy at Guggenheim
12/15
07:14 pm
kros
Keros Therapeutics downgraded to Neutral from Buy at Guggenheim
Medium
Report
Keros Therapeutics downgraded to Neutral from Buy at Guggenheim
12/13
02:45 pm
kros
Rating for KROS
Medium
Report
Rating for KROS
12/13
02:45 pm
kros
Rating for KROS
Medium
Report
Rating for KROS
12/12
02:10 pm
kros
Rating for KROS
Low
Report
Rating for KROS
12/12
02:10 pm
kros
Rating for KROS
Low
Report
Rating for KROS
12/12
12:47 pm
kros
Rating for KROS
Low
Report
Rating for KROS
12/12
09:48 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
High
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
12/12
09:48 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
High
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
12/12
09:48 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
High
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
12/12
09:30 am
kros
Keros Therapeutics downgraded to Market Perform from Outperform at William Blair
Low
Report
Keros Therapeutics downgraded to Market Perform from Outperform at William Blair
12/12
09:30 am
kros
Keros Therapeutics downgraded to Market Perform from Outperform at William Blair
Low
Report
Keros Therapeutics downgraded to Market Perform from Outperform at William Blair
12/12
09:12 am
kros
Keros Therapeutics downgraded to Neutral from Buy at BTIG
Low
Report
Keros Therapeutics downgraded to Neutral from Buy at BTIG
12/11
10:23 am
kros
Rating for KROS
Low
Report
Rating for KROS
12/11
10:23 am
kros
Rating for KROS
Low
Report
Rating for KROS
12/5
09:01 am
kros
Rating for KROS
Medium
Report
Rating for KROS
12/5
09:01 am
kros
Rating for KROS
Medium
Report
Rating for KROS
12/4
09:00 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at Guggenheim.
High
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at Guggenheim.
12/4
09:00 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at Guggenheim.
High
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at Guggenheim.